Citations

Clear

6421 citation(s) found for "Su, Christopher".

Two-year Efficacy and Safety of Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Terrier, B., Hellmich, B., Specks, U., Sjö, Lena Börjesson, Ho, C.N. , Jison, Maria, McCrae, Christopher , Necander, S., Rodríguez‐Suárez, Eva, Shavit, A., Wechsler, Michael E , Nair, Parameswaran K. , Khalidi, Nader , Terrier, Benjamin , Bourdin, Arnaud , Jayne, David , Jackson, David J. , Roufosse, Florence , Pagnoux, Christian , Specks, Ulrich , Shavit, Anat , Walton, C., Merkel, Peter A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5029-A5029

10.1164/ajrccm.2025.211.abstracts.a5029 Get It

Abstract Rationale: The 1-year double-blind period of the MANDARA trial (NCT04157348) demonstrated non-inferiority of benralizumab to mepolizumab for achieving remission, in adults with relapsing/refractory eosinophilic granulomatosis with polyangiitis (EGPA). Here, we report the 2-year combined double-blind and ongoing open-label extension (OLE) data. Methods: On completion of the double-blind period (n=136/140) comparing benralizumab 1x30mg versus mepolizumab 3x100mg subcutaneously every 4 weeks, patients were invited to enter the OLE where they continued benralizumab (benra/benra) or switched from mepolizumab to benralizumab (mepo/benra). Endpoints included remission (Birmingham Vasculitis Activity Score=0 and oral glucocorticoid [OGC[ dose ≤4 mg/day), OGC use, relapse, blood eosinophil count (bEOS), Asthma Control Questionnaire (ACQ-6), pre-bronchodilator forced expiratory volume in 1 second (pre-BD FEV1), and safety. Results: In total, 128 patients entered the OLE (n=66 benra/benra, n=62 mepo/benra; mean age 52.8 years; 60.2% female), and 119 completed OLE Year 1. Baseline characteristics of those entering the OLE were similar to the double-blind period. At Week 104, over 60% in both groups (41 [62.1%] benra/benra and 42 [67.7%] mepo/benra patients) achieved remission. During the OLE, 51 (77.3%) benra/benra and 42 (67.7%) mepo/benra patients had no relapses. The percentage of benra/benra patients who discontinued OGCs was similar at Weeks 49-52 (27 [40.9%]) and Weeks 101-104 (29 [43.9%]), while the percentage increased for mepo/benra patients between Weeks 49-52 (16 [25.8%]) and Weeks 101-104 (27 [43.5%]; Figure). The median (IQR) OGC dose at Weeks 101-104 was 0.5 (0,5) in benra/benra and 1.36 (0,5) mg/day in mepo/benra patients. The median (IQR) bEOS in benra/benra patients was 20 (10,40) cells/µL at both Weeks 52 and 100; bEOS were depleted in mepo/benra patients from 70 (40,90) cells/µL to 20 (10,50) cells/µL by 4 weeks after switching. Mean (SD) ACQ-6 scores were 0.64 (0.78) in benra/benra patients and 0.60 (0.76) in mepo/benra patients at Week 104 compared with 1.39 (1.18) and 1.11 (0.95) at baseline. Mean (SD) pre-BD FEV1 was 2.59 (0.90) L versus 2.62 (0.84) L in benra/benra versus mepo/benra patients at Week 52, and 2.61 (0.90) versus 2.63 (0.81) L, at Week 100. Safety of mepolizumab and benralizumab was consistent with their known profiles. Conclusions: In patients with EGPA receiving benralizumab, remission rates, OGC discontinuation, and bEOS depletion were durable over 104 weeks with low relapse rates, and without loss of asthma control or lung function decline. Additional bEOS depletion and OGC sparing was observed in patients switching from mepolizumab to benralizumab.
Nebulized Platelet-derived Extracellular Vesicles Attenuate Cigarette Smoke-induced Murine Emphysema Via Immunoregulation
Wang, Supeng, Stalboerger, Paul G., Paradise, Christopher J. , MaCranor, B., Daher, A., Du, D., Behfar, Atta , Paradise, C., Vassallo, R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3050-A3050

10.1164/ajrccm.2025.211.abstracts.a3050 Get It

Abstract Rationale: We previously reported (PMID: 38325750) that a nebulized exosome product isolated from human platelets (PEP) attenuated murine cigarette smoke (CS)-induced emphysema. To further elucidate the mechanism by which PEP attenuates CS-induced effects in the murine lung, emphysema was induced, and mice were treated with PEP or placebo (saline). Immune and cellular mechanisms affected by PEP were then evaluated in this system. Methods: C57BL6 female black mice were exposed to CS 5 days a week for 3 months and then randomized into PEP-treated or placebo groups. CS-exposed mice were treated with 3 mL of 7.5 mg/mL PEP (∼1 x 1010 extracellular vesicles per mL) or 0.9% saline by nebulization 3 times a week for an additional 4 weeks, using a nose-sealed, pressure and humidity-controlled inhalation tower for 30 minutes. Lung compliance, cutaneous O2 saturation, mean linear intercepts, and lung inflammation were measured during and after the study. Lung tissue was further analyzed by immunostaining, and gene expression analyses to elucidate the molecular mechanisms of PEP's action. Inflammatory and immune regulatory cell markers evaluated included CD4 (CD4+ T lymphocytes), CD4/Foxp3 (T regulatory – Treg) cells, S100A9 (interstitial lung macrophages), and myeloperoxidase (MPO) for neutrophils. Results: Histologic review of lung tissue sections by mean linear intercept counts confirmed prior findings and showed a significant reduction in the free distance of chronic CS exposure-induced alveolar space enlargement in PEP-treated mice (P=0.003). In addition, lung inflammation scores showed a significant overall reduction of the lymphocytic infiltrates in PEP-nebulized lungs compared to the CS-exposed placebo control group (P<0.0001). Further analysis of the immune cell infiltrates revealed increased FOXP3+CD4+ T regulatory cells within the lymphocytic infiltrates (P<0.0001) and decreased S100A9+ interstitial lung macrophages (p=0.0002) and MPO+ neutrophils (p=0.005) in PEP nebulized lungs compared to the placebo controls. PEP-treated mice had similar oxygen saturation levels when compared to the CS control group (94.7±1.47 vs. 95.4±.1.6 respectively). Conclusions: In addition to validating prior findings on the effect of nebulized PEP in mitigating CS-induced murine lung injury and emphysema, the current data suggests an immunoregulatory role for PEP by decreasing inflammatory macrophage and neutrophil infiltration while augmenting anti-inflammatory Treg cell numbers in the lung.
Aortoenteric Fistulas Following Endovascular Aortic Aneurysm Repair: A Review
Rey, Jorge , Bornak, Arash , Montoya, Christopher , Polania, Camilo A., Kang, Naixin , Sussman, Matthew , Gonzalez, Kathy , Polanía-Sandoval, Camilo , Polania, Camilo, Polania-Sandoval, Camilo A , Kenel-Pierre, Stefan C. , Sussman, Matthew, Erben, Young

Mayo Clinic

Vascular and Endovascular Surgery | May 9, 2025 | Volume: 59 | Issue: 7 | Pages: 695-705

10.1177/15385744251339966 | PMID 40340624 Get It

Background Secondary aortoenteric fistulas (SAEF) following endovascular aortic repair (EVAR) is an extremely rare event but life threatening. Our review offers comprehensive knowledge on pathophysiology, clinical presentation, diagnosis, and treatment options. Aim To summarize the current literature regarding pathophysiology, clinical, diagnostic and therapeutic approach of aortoenteric fistulas secondary to EVAR. Methods We performed a literature search in Pubmed/MEDLINE to identify the literature published about SAEF after EVAR. Cases were summarized in a table and prevalences. Other relevant literature was included in the results sections. Results A total of 35 reports (single cases and small series) with 45 patients were included. SAEF after EVAR can result from infection, inflammation, or mechanical factors. Clinical presentation is often non-specific, ranging from a gastrointestinal herald bleed to hemorrhagic shock, or malaise and general infection-related symptoms. Cross-sectional imaging plays a critical role in diagnosing SAEF. The treatment approach involves a multidisciplinary team approach and requires broad-spectrum intravenous antibiotics, endovascular intervention for urgent hemorrhage control, and open surgical intervention for definitive repair. Long-term antimicrobial therapy is essential to avoid reinfection. Conclusions SAEF following EVAR represents a complex, life-threatening condition with limited evidence-based management strategies. Given the growing prevalence of endovascular procedures, comprehensive knowledge of SAEF is crucial for all health care providers to improve early diagnosis and outcomes.
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry , Costello, Caitlin , D’Angelo, Christopher R. , Derman, Benjamin A. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Robinson, Timothy, Valent, Jason , Varshavsky‐Yanovsky, Asya, Kovách, E, Holmberg, Leona , Anderson, Larry D. , Anderson, Larry D , Derman, Benjamin A , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Devarakonda, Srinivas , Kang, Yubin , Lee, Hans C. , Martin, Thomas G. , Rosenberg, Aaron , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovach, Emily, Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 132-140

10.6004/jnccn.2025.0023 | PMID 40340857 Get It

The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Ajani, Jaffer A. , D’Amico, Thomas A., Bentrem, David J., Corvera, Carlos U. , Das, Prajnan , Enzinger, Peter C. , Enzler, Thomas , Gerdes, Hans, Grierson, Patrick , Hofstetter, Wayne L. , Ilson, David H. , Jalal, Shadia I. , Kleinberg, Lawrence , Lacy, Jill , Lee, Byrne , Licciardi, Frank, Ly, Quan P. , Matsukuma, Karen , McNamara, Michael, Mukherjee, Sarbajit , Mulcahy, Mary F. , Reddi, Deepti , Reznik, Scott I. , Roses, Robert E. , Strong, Vivian E. , Su, Stacey, Uboha, Nataliya V. , Willett, Christopher G. , Yoon, Harry H. , McMillian, Nicole R., Stein, MaryElizabeth , Gupta, Garima , Ajani, Jaffer A , Bentrem, David J. , Gibson, Michael K. , Gupta, Garima , Kim, Sunnie S. Y. , Klempner, Samuel J. , Lloyd, Shane , Merkow, Ryan P. , Perry, Kyle A. , Pimiento, José M. , Reddi, Deepti , Wainberg, Zev A. , Woo, Yanghee

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 169-191

10.6004/jnccn.2025.0022 | PMID 40341199 Get It

Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.
Combined immune checkpoint inhibitors and ablative radiotherapy in metastatic cancers: a meta-analysis of prospective clinical trials
Urias, Eduardo , Lee, Jaehoon , Weil, Christopher R. , Roach, Eric , Hashibe, Mia, Facciabene, Andrea , Maity, Amit , Tao, Randa , Weil, Christopher R , Lloyd, Shane

Mayo Clinic

BMJ Oncology | May 8, 2025 | Volume: 4 | Issue: 1 | Pages: e000732

10.1136/bmjonc-2025-000732 | PMID 40357050 Get It

Objective To pool data from prospective clinical trials investigating combined stereotactic ablative radiotherapy (SABR) with immune checkpoint inhibitors (ICI) in patients with metastatic cancers. Methods and analysis PubMed, Scopus and EMBASE were queried for full-length articles of prospective clinical trials involving patients with metastatic solid tumours. Random-effects meta-analysis was performed with the Knapp-Hartung method. Multilevel regression analyses with primary cancers used as random effects and pairwise comparisons with two-tailed test adjusted with Benjamini-Hochberg method were performed. Regression coefficients (β) were calculated to assess the correlation between dose and outcomes. Results We identified 30 trials and 35 individual treatment arms with a total of 951 patients with at least one outcome metric reported. Large heterogeneity was identified for all outcomes measured (I 2 range: 75%–86%). The pooled rate of grade 3+ treatment-related adverse events was 18% (95% CI 11% to 24%). The progression-free survival (PFS) and overall survival (OS) at 6 months were 27% (95% CI 19% to 36%) and 67% (95% CI 59% to 76%), respectively. On multilevel regression, we identified improvement in 6-month PFS (β=0.6, p=0.003) and OS (β=1.6, p=0.04) with increasing BED10Gy doses. Combined-target ICI correlated with better 6-month OS when compared with αPD-1/PD-L1 alone. Conclusion We report a safety profile of combined ICI with SABR in patients with metastatic cancer that is comparable to that of ICI alone. We identified higher doses of radiotherapy and dual-target ICI to be associated with better OS at 6 months. Large heterogeneity and the lack of a control group limit the interpretation of our findings.
A human and mouse subpopulation of senescent β-cells induces pathologic dysfunction through targetable paracrine signaling
Carapeto, Priscila , Abarca, Cristian , Hela, Francesko , Sanjines, Stephanie, Pena, Sebastian, Le, Sandra M., Cahill, Christopher, Midha, Ayush , Baker, Dylan , Espinoza, Sara , Cigarroa, Francisco , Woolworth, Jillian L., Kirkland, James L. , Musi, Nicolas , Aguayo‐Mazzucato, Cristina , Iwasaki, Kanako , Carapeto, Priscila , Abarca, Cristian , Hela, Francesko , Midha, Ayush , Domanskyi, Sergii , Chuang, Jeffrey H , Kuchel, George A , Robson, Paul , Aguayo-Mazzucato, Cristina , Pena, Alejandro , Iwasaki, Kanako , Pena, Sebastian, Pan, Hui , Alcoforado Diniz, Juliana , Domanskyi, Sergii , Espinoza, Sara, Pena, Alejandro, Garovic, Vesna D. , Tchkonia, Tamar , Kuchel, George A. , Robson, Paul

Mayo Clinic

No container title available | May 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.07.648438 | PMID 40654723 Get It

ABSTRACT Cellular senescence is a stress response mechanism marked by irreversible growth arrest, upregulation of antiapoptotic pathways, loss of cellular function, and remodelling of the cellular secretory profile. In both humans and mice, pancreatic β-cells undergo senescence with age and insulin resistance. Targeted removal of senescent cells in mouse models of diabetes improves glucose homeostasis, demonstrating the role β-cell senescence in diabetes progression. In contrast, β-cell senescence also promotes immune surveillance, promoting β-cell survival and function. Thus, a better understanding of senescent cells’ phenotypic and functional heterogeneity is needed to develop effective therapeutic strategies. Herein, we show that subpopulations of senescent β-cells in mice and humans, which were identified through the expression of Cdkn1a (encoding p21 Cip1 ) and Cdkn2a (encoding p16 Ink4a ) by single-cell RNA sequencing (scRNA-seq), flow cytometry, spatial transcriptomics, and spatial proteomics, exhibit distinct transcriptional and functional identities. The predominant senescent β-cell subpopulation expressed Cdkn1a and was characterized by a lack of glucose responsiveness, high basal insulin secretion, and transcription of canonical SASP factors. The SASP of Cdkn1a -expressing β-cells had non-cell autonomous effects on neighbouring cells. A subset of four SASP factors from Cdkn1a + cells was sufficient to induce secondary senescence and β-cell dysfunction in vitro . JAK inhibitors (JAK1/2 and JAK1/3) counteracted secondary senescence induction and restored β-cell function in high-fat diet-fed mice and human islets from donors with or without type 2 diabetes. GRAPHICAL ABSTRACT
Artificial Intelligence: The New Transplant Selection Committee Member
Lee, Frank G. , Kim, Christopher , Diwan, Tayyab S. , Kim, Christopher H. , Lee, Frank G

Mayo Clinic

Bioethics | May 7, 2025 | Volume: 39 | Issue: 7 | Pages: 725-726

10.1111/bioe.13430 | PMID 40331531 Get It

In nonsevere influenza, antiviral drugs do not reduce mortality or hospital admissions; some shorten symptom duration
Clements, Casey M. , Carpenter, Christopher R.

Mayo Clinic

Annals of Internal Medicine | May 5, 2025 | Volume: 178 | Issue: 5 | Pages: JC51

10.7326/annals-25-01324-jc | PMID 40324181 Get It

Clinical Outcomes of Mitral Regurgitation Severity and Transcatheter Edge‐to‐Edge Repair in Atrial Functional Mitral Regurgitation
Naser, Jwan A. , Massad, Faysal, Borlaug, Barry A. , Simard, Trevor , Siontis, Konstantinos C. , Kennedy, Austin M , Thaden, Jeremy J. , Eleid, Mackram F. , Borlaug, Barry A , Simard, Trevor , Eleid, Mackram F , Naser, Jwan A , Scott, Christopher G. , Michelena, Héctor I. , Pellikka, Patricia A. , Nkomo, Vuyisile T. , Pislaru, Sorin V.

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 5, 2025 | Volume: 106 | Issue: 1 | Pages: 494-503

10.1002/ccd.31567 | PMID 40320723 Get It

ABSTRACT Background Incident atrial functional mitral regurgitation (AFMR) is associated with mortality. Transcatheter edge‐to‐edge repair (TEER) has shown effectiveness in improving MR and symptoms in AFMR, but previous studies lacked comparison to conservative management. We aimed to study the association of AFMR severity and mitral TEER with symptoms, heart failure hospitalizations (HFH) and all‐cause mortality in moderate/severe AFMR. Methods Consecutive adults with moderate/severe AFMR managed conservatively or with TEER 2010−2023 were identified retrospectively. To ensure similar technique in evaluation in the two groups, variables were obtained from the closest transthoracic echocardiogram before TEER in the TEER group. In addition to multivariable analysis, the association of TEER (vs. conservative management) with HFH and mortality was assessed using propensity‐score matched analyses; the propensity score was based on age, sex, EuroSCORE II, effective regurgitant orifice area, integrative MR severity, and NYHA class III/IV (vs. I/II). Results Among 230 patients with moderate/severe AFMR [mean age 77; 56% females], 46 were managed with TEER. Severe (vs. moderate) AFMR was independently associated with baseline NYHA class III/IV (multivariable OR 2.18 [95% CI 1.13−4.26]) and HFH [multivariable HR 2.75 (95% CI 1.25−6.03)] but not mortality ( p = 0.26). TEER improved MR to ≤ moderate in 93% but was not associated with lower HFH or death rates versus conservative management on multivariable or matched analysis. However, 1‐year NYHA improved more with TEER versus conservative management in patients with baseline NYHA class III/IV (62% vs. 27%, p = 0.03). Rhythm control was associated with improved survival (HR 0.38 [0.15−0.98]). Conclusions AFMR severity was associated with symptoms and HFH but not mortality. MR severity and NYHA class improved with TEER, but the association of TEER with HF hospitalizations or death remains unproven. Randomized studies are needed to evaluate the potential role of TEER and rhythm control on outcomes in AFMR.